Eli Lilly and Company has announced Philip Johnson has been appointed to senior vice president, Finance, and treasurer effective January 1, 2018.
Johnson currently serves as vice president for Investor Relations at Lilly. He will report to Joshua Smiley, who will become senior vice president and chief financial officer effective January 1, 2018. Johnson will continue to lead Lilly’s investor relations efforts.
“Phil has been a trusted partner for our shareholders, effectively communicating the company’s results and expectations, while ensuring management’s actions are informed by shareholder input,” Smiley said. “With his external focus and experience in the capital markets, Phil is an ideal candidate to assume this important position and to help guide Lilly’s financial strategy.”
Johnson has been with Lilly 22 years, serving in a variety of financial roles in the U.S. and overseas. He has been in his current role since 2007 and before that was vice president, Finance, and chief financial officer for Global Manufacturing and Quality. Prior to joining Lilly, Johnson worked for six years in investment banking and management consulting in the U.S. and Europe.
Source: Eli Lilly and Company
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
